Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms

Ruziana Masiran, Hatta Sidi, Zahurin Mohamed, Nur Elia Nur, Nik Ruzyanei Nik Jaafar, Marhani Midin, Srijit Das, Suriati Mohamed Saini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Selective serotonin reuptake inhibitors (SSRIs) are known for their sexual side effects. Different SSRIs may affect different areas of sexual function at different rates. Aims: The study aimed to determine the prevalence of female sexual dysfunction (FSD), its clinical correlates, and association with 5HT2A (rs6311) single nucleotide polymorphisms (SNPs) in patients with major depressive disorder (MDD) who were on SSRI therapy. Methods: This was a cross-sectional study on 95 female outpatients with MDD treated with SSRI. The patients were in remission as determined by Montgomery-Asberg Depression Rating Scale. Genomic DNA was isolated from buccal swabs and samples were processed using a real time polymerase chain reaction. Main Outcome Measures: The presence or absence of FSD as measured by the Malay Version of Female Sexual Function Index and 5HT2A-1438 G/A (rs6311) SNP. Results: The overall prevalence of FSD was 32.6%. After controlling for age, number of children, education level, total monthly income, SSRI types, and SSRI dosing, being employed significantly enhanced FSD by 4.5 times (odds ratio [OR]=4.51; 95% confidence interval [CI] 1.00, 20.30; P=0.05). Those having marital problems were 6.7 times more likely to have FSD (OR=6.67; 95% CI 1.57, 28.34). 5HT2A-1438 G/A (rs6311) SNP was not significantly associated with FSD. Conclusion: There was no significant association between FSD and the 5HT2A (rs6311) SNP in patients with MDD on SSRI therapy. Employment status and marital state were significantly associated with FSD among these patients. Masiran R, Sidi H, Mohamed Z, Mohd. Nazree NE, Nik Jaafar NR, Midin M, Das S, and Mohamed Saini S. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.

Original languageEnglish
Pages (from-to)1047-1055
Number of pages9
JournalJournal of Sexual Medicine
Volume11
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Major Depressive Disorder
Serotonin Uptake Inhibitors
Single Nucleotide Polymorphism
Serotonin
1,7,9,11-tetrahydroxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenzo(a)tetracene-2-carboxylic acid
Odds Ratio
Confidence Intervals
Cheek
Real-Time Polymerase Chain Reaction
Outpatients
Cross-Sectional Studies
Outcome Assessment (Health Care)
Depression
Education

Keywords

  • 5HT2A polymorphisms
  • Female sexual dysfunction
  • Major depressive disorder
  • Selective serotonin reuptake inhibitor antidepressant treatment
  • Serotonin 2A polymorphisms
  • SSRI-Induced female sexual dysfunction

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

@article{feec9610a1fb47a69283045c63784158,
title = "Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms",
abstract = "Introduction: Selective serotonin reuptake inhibitors (SSRIs) are known for their sexual side effects. Different SSRIs may affect different areas of sexual function at different rates. Aims: The study aimed to determine the prevalence of female sexual dysfunction (FSD), its clinical correlates, and association with 5HT2A (rs6311) single nucleotide polymorphisms (SNPs) in patients with major depressive disorder (MDD) who were on SSRI therapy. Methods: This was a cross-sectional study on 95 female outpatients with MDD treated with SSRI. The patients were in remission as determined by Montgomery-Asberg Depression Rating Scale. Genomic DNA was isolated from buccal swabs and samples were processed using a real time polymerase chain reaction. Main Outcome Measures: The presence or absence of FSD as measured by the Malay Version of Female Sexual Function Index and 5HT2A-1438 G/A (rs6311) SNP. Results: The overall prevalence of FSD was 32.6{\%}. After controlling for age, number of children, education level, total monthly income, SSRI types, and SSRI dosing, being employed significantly enhanced FSD by 4.5 times (odds ratio [OR]=4.51; 95{\%} confidence interval [CI] 1.00, 20.30; P=0.05). Those having marital problems were 6.7 times more likely to have FSD (OR=6.67; 95{\%} CI 1.57, 28.34). 5HT2A-1438 G/A (rs6311) SNP was not significantly associated with FSD. Conclusion: There was no significant association between FSD and the 5HT2A (rs6311) SNP in patients with MDD on SSRI therapy. Employment status and marital state were significantly associated with FSD among these patients. Masiran R, Sidi H, Mohamed Z, Mohd. Nazree NE, Nik Jaafar NR, Midin M, Das S, and Mohamed Saini S. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.",
keywords = "5HT2A polymorphisms, Female sexual dysfunction, Major depressive disorder, Selective serotonin reuptake inhibitor antidepressant treatment, Serotonin 2A polymorphisms, SSRI-Induced female sexual dysfunction",
author = "Ruziana Masiran and Hatta Sidi and Zahurin Mohamed and Nur, {Nur Elia} and {Nik Jaafar}, {Nik Ruzyanei} and Marhani Midin and Srijit Das and {Mohamed Saini}, Suriati",
year = "2014",
doi = "10.1111/jsm.12452",
language = "English",
volume = "11",
pages = "1047--1055",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms

AU - Masiran, Ruziana

AU - Sidi, Hatta

AU - Mohamed, Zahurin

AU - Nur, Nur Elia

AU - Nik Jaafar, Nik Ruzyanei

AU - Midin, Marhani

AU - Das, Srijit

AU - Mohamed Saini, Suriati

PY - 2014

Y1 - 2014

N2 - Introduction: Selective serotonin reuptake inhibitors (SSRIs) are known for their sexual side effects. Different SSRIs may affect different areas of sexual function at different rates. Aims: The study aimed to determine the prevalence of female sexual dysfunction (FSD), its clinical correlates, and association with 5HT2A (rs6311) single nucleotide polymorphisms (SNPs) in patients with major depressive disorder (MDD) who were on SSRI therapy. Methods: This was a cross-sectional study on 95 female outpatients with MDD treated with SSRI. The patients were in remission as determined by Montgomery-Asberg Depression Rating Scale. Genomic DNA was isolated from buccal swabs and samples were processed using a real time polymerase chain reaction. Main Outcome Measures: The presence or absence of FSD as measured by the Malay Version of Female Sexual Function Index and 5HT2A-1438 G/A (rs6311) SNP. Results: The overall prevalence of FSD was 32.6%. After controlling for age, number of children, education level, total monthly income, SSRI types, and SSRI dosing, being employed significantly enhanced FSD by 4.5 times (odds ratio [OR]=4.51; 95% confidence interval [CI] 1.00, 20.30; P=0.05). Those having marital problems were 6.7 times more likely to have FSD (OR=6.67; 95% CI 1.57, 28.34). 5HT2A-1438 G/A (rs6311) SNP was not significantly associated with FSD. Conclusion: There was no significant association between FSD and the 5HT2A (rs6311) SNP in patients with MDD on SSRI therapy. Employment status and marital state were significantly associated with FSD among these patients. Masiran R, Sidi H, Mohamed Z, Mohd. Nazree NE, Nik Jaafar NR, Midin M, Das S, and Mohamed Saini S. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.

AB - Introduction: Selective serotonin reuptake inhibitors (SSRIs) are known for their sexual side effects. Different SSRIs may affect different areas of sexual function at different rates. Aims: The study aimed to determine the prevalence of female sexual dysfunction (FSD), its clinical correlates, and association with 5HT2A (rs6311) single nucleotide polymorphisms (SNPs) in patients with major depressive disorder (MDD) who were on SSRI therapy. Methods: This was a cross-sectional study on 95 female outpatients with MDD treated with SSRI. The patients were in remission as determined by Montgomery-Asberg Depression Rating Scale. Genomic DNA was isolated from buccal swabs and samples were processed using a real time polymerase chain reaction. Main Outcome Measures: The presence or absence of FSD as measured by the Malay Version of Female Sexual Function Index and 5HT2A-1438 G/A (rs6311) SNP. Results: The overall prevalence of FSD was 32.6%. After controlling for age, number of children, education level, total monthly income, SSRI types, and SSRI dosing, being employed significantly enhanced FSD by 4.5 times (odds ratio [OR]=4.51; 95% confidence interval [CI] 1.00, 20.30; P=0.05). Those having marital problems were 6.7 times more likely to have FSD (OR=6.67; 95% CI 1.57, 28.34). 5HT2A-1438 G/A (rs6311) SNP was not significantly associated with FSD. Conclusion: There was no significant association between FSD and the 5HT2A (rs6311) SNP in patients with MDD on SSRI therapy. Employment status and marital state were significantly associated with FSD among these patients. Masiran R, Sidi H, Mohamed Z, Mohd. Nazree NE, Nik Jaafar NR, Midin M, Das S, and Mohamed Saini S. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms.

KW - 5HT2A polymorphisms

KW - Female sexual dysfunction

KW - Major depressive disorder

KW - Selective serotonin reuptake inhibitor antidepressant treatment

KW - Serotonin 2A polymorphisms

KW - SSRI-Induced female sexual dysfunction

UR - http://www.scopus.com/inward/record.url?scp=84897498706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897498706&partnerID=8YFLogxK

U2 - 10.1111/jsm.12452

DO - 10.1111/jsm.12452

M3 - Article

VL - 11

SP - 1047

EP - 1055

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 4

ER -